Japan 2022 Review/Outlook: Supply Crisis, Incentives, Cost Controls In Focus

Balance Of Give And Take

As Japan's pharma market continues to face supply chain challenges and rising healthcare costs, regulatory authorities are looking to policies that balance incentives in critical areas and temporary price rises with other other ongoing measures to contain the national drugs bill. The Pink Sheet takes a look at the key changes last year and what to expect in 2023.

Japan 2022/2023
Japan announced its plan for the "mid-year" pricing review for FY2023 • Source: Shutterstock

Japan’s pharmaceutical industry continued to suffer from a years-long distribution crisis in 2022, which especially affected generic products despite a year that saw surging demand from medical institutions amid repeated local waves of the COVID-19 pandemic.

More from Japan

PhRMA, EFPIA Threaten Japan Council Pull-Out Over Venture Fund Plan

 
• By 

Major foreign pharma industry groups in Japan are threatening to pull out of a planned public-private council initiative over a proposed sales tax on certain drugs to fund drug discovery.

Japan’s 2025 ‘Off-Year’ Price Cut Stirs Deeper Concerns

 
• By 

Multiple industry groups in Japan warn that a decision to implement an "off-year" drug price revision in April will reverse other recent policy moves to support innovation.

Political Shifts Shake Up Japan Price Cut Debate

 
• By 

A shifting political power balance in Japan is leading to renewed debate on the pace of regular drug reimbursement price cuts.

Japan Recommends Approval Of Dato-DXd, Sipavibart

 
• By 

Formal full official approvals for both products expected by early January, which would in both cases be the first to be granted worldwide.

More from Asia